| 前收市價 | 3.7000 |
| 開市 | 3.7000 |
| 買盤 | 2.8500 |
| 賣出價 | 4.4500 |
| 拍板 | 155.00 |
| 到期日 | 2025-06-20 |
| 今日波幅 | 3.7000 - 3.7000 |
| 合同範圍 | 無 |
| 成交量 | |
| 未平倉合約 | 264 |
BenzingaMerck Reports Progress On The Cancer Front As It Prepares For Keytruda Patent Expiration
After topping expectations with first quarter revenue and adjusted earnings last week, Merck & Co Inc (NYSE: MRK) just reported encouraging data from its Phase III gastric cancer treatment trial after ending 2023 with good news from its combined treatment with Moderna Inc (NASDAQ: MRNA) in fighting melanoma. Merck reported improvement in cancer patients receiving its Keytruda regimen. Enrolling 698 subjects, the trial evaluated the effect of a treatment that combines Merck’s immunotherapy blockb
Insider Monkey15 Best Places to Retire in Florida That You’ve Never Heard Of
This article takes a look at the 15 best places to retire in Florida that you’ve never heard of. If you wish to skip our detailed analysis of financial challenges and hidden gems in Florida, you may go to the 5 Best Places to Retire in Florida That You’ve Never Heard Of. Navigating Financial Challenges […]
Insider MonkeyMerck & Co., Inc. (NYSE:MRK) Q1 2024 Earnings Call Transcript
Merck & Co., Inc. (NYSE:MRK) Q1 2024 Earnings Call Transcript April 25, 2024 Merck & Co., Inc. beats earnings expectations. Reported EPS is $2.07, expectations were $1.94. Merck & Co., Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Thank […]
